文献速递呼吸道感染

苯二氮䓬受体激动剂使用与肺炎住院风险:全国性巢式病例对照研究

The Use of Benzodiazepine Receptor Agonists and the Risk of Hospitalization for Pneumonia: A Nationwide Population-Based Nested Case-Control Study.
PubMed 文献 · Chest · 2017-08-04

该研究基于台湾全民健康保险研究数据库(2002-2012年),纳入12,002例肺炎住院患者及12,002例疾病风险评分匹配的对照,评估苯二氮䓬受体激动剂(BZRA)使用与肺炎住院的关联。结果显示当前BZRA暴露与肺炎住院风险升高相关(aOR 1.86),且存在剂量反应关系,其中苯二氮䓬类催眠药(尤其咪达唑仑)风险更高。

要点

  • 当前BZRA暴露与肺炎住院风险升高相关(aOR 1.86,95%CI 1.75-1.97)。
  • 苯二氮䓬类催眠药风险高于抗焦虑药或非苯二氮䓬类催眠药。
  • 超短效及短至中效药物、较高限定日剂量及联用多种BZRA时风险增加。

核心结论

  • 当前BZRA使用与肺炎住院风险存在剂量反应关系。
  • 苯二氮䓬类催眠药尤其咪达唑仑与肺炎住院风险更高相关。

研究设计与样本

  • 研究为基于台湾全民健康保险研究数据库(2002-2012年)的全国性巢式病例对照研究。
  • 仅纳入前2年无BZRA处方的初治使用者,共12,002例肺炎住院患者和12,002例疾病风险评分匹配的对照。
  • 采用逻辑回归模型评估BZRA使用与肺炎住院的关联,并全面评估暴露日期、剂量反应关系及BZRA类别。

主要发现

  • 当前BZRA暴露与肺炎住院相关(aOR 1.86;95% CI 1.75-1.97)。
  • 苯二氮䓬类催眠药(aOR 2.42;95% CI 2.16-2.71)风险高于苯二氮䓬类抗焦虑药(aOR 1.53;95% CI 1.44-1.63)或非苯二氮䓬类催眠药(aOR 1.60;95% CI 1.46-1.76)。
  • 超短效及短至中效药物、较高限定日剂量及联用BZRA数量增加时肺炎风险升高。
  • 在 examined 的单个BZRA中,咪达唑仑的肺炎住院风险较高(aOR 5.77;95% CI 4.31-7.73)。

临床怎么用

  • 处方BZRA时应仔细权衡获益与风险,尤其对肺炎高危患者。
  • 优先考虑风险较低的BZRA类别或避免不必要的BZRA使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationship between the use of benzodiazepine-receptor agonists (BZRAs) and the risk of hospitalization for pneumonia remains inconclusive. This study aimed to explore the association between BZRA use and hospitalization for pneumonia in a general population. METHODS: This population-based nested case-control study used Taiwan's National Health Insurance Research Database between 2002 and 2012. We included only new users who did not have any BZRA prescriptions on record in the preceding 2 years and identified 12,002 subjects who were hospitalized for pneumonia (International Classification of Diseases, Ninth Revision codes 480-486, and 507) and 12,002 disease risk score-matched control subjects. A logistic regression model was used to determine the association of BZRA use and hospitalization for pneumonia. The exposure date, dose-response relationship, and class of BZRAs were comprehensively assessed. RESULTS: Current BZRA exposure was associated with hospitalization for pneumonia (adjusted OR [aOR],1.86; 95% CI, 1.75-1.97). Benzodiazepine hypnotic agents (aOR, 2.42; 95% CI, 2.16-2.71) had a higher risk of pneumonia than did benzodiazepine anxiolytic agents (aOR, 1.53; 95% CI, 1.44-1.63) or nonbenzodiazepine hypnotic agents (aOR, 1.60; 95% CI, 1.46-1.76). The pneumonia risk was increased with ultrashort-acting and short- to intermediate-acting agents, a higher defined daily dose, and the number of BZRAs used. Among individual BZRAs examined, midazolam had a higher risk (aOR, 5.77; 95% CI, 4.31-7.73) of hospitalization for pneumonia than did the others. CONCLUSIONS: This study suggests that there is a dose-response relationship between current BZRA use and the risk of hospitalization for pneumonia. In addition, benzodiazepine hypnotic agents, especially midazolam, present a greater risk of hospitalization for pneumonia. These findings reinforce the importance of a careful analysis of the benefits vs the risks of BZRA use.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Chen TY, Winkelman JW, Mao WC, et al. The Use of Benzodiazepine Receptor Agonists and the Risk of Hospitalization for Pneumonia: A Nationwide Population-Based Nested Case-Control Study. Chest. 2017. PMID: 28782528. doi:10.1016/j.chest.2017.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。